Genexine Inc (095700) - Total Liabilities

Latest as of September 2025: ₩106.21 Billion KRW ≈ $71.98 Million USD

Based on the latest financial reports, Genexine Inc (095700) has total liabilities worth ₩106.21 Billion KRW (≈ $71.98 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Genexine Inc - Total Liabilities Trend (2009–2024)

This chart illustrates how Genexine Inc's total liabilities have evolved over time, based on quarterly financial data. See Genexine Inc (095700) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Genexine Inc Competitors by Total Liabilities

The table below lists competitors of Genexine Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Casino Guichard Perrachon SA PA:CO	France	€6.62 Billion
Sao Ta Foods JSC VN:FMC	Vietnam	₫1.79 Trillion
OM INFRA LIMITED NSE:OMINFRAL	India	Rs6.58 Billion
Anfield Energy Inc. NASDAQ:AEC	USA	$37.29 Million
Viet Nam Power Development JSC VN:VPD	Vietnam	₫93.86 Billion
Kino Indonesia Tbk PT JK:KINO	Indonesia	Rp2.81 Trillion
First US Bancshares Inc NASDAQ:FUSB	USA	$1.06 Billion
Fast Ejendom CO:FED	Denmark	Dkr924.33 Million

Liability Composition Analysis (2009–2024)

This chart breaks down Genexine Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Genexine Inc (095700) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	0.58	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.41	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.29	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Genexine Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Genexine Inc (2009–2024)

The table below shows the annual total liabilities of Genexine Inc from 2009 to 2024.

Year	Total Liabilities	Change
2024-12-31	₩83.36 Billion ≈ $56.49 Million	+4.62%
2023-12-31	₩79.68 Billion ≈ $54.00 Million	-29.25%
2022-12-31	₩112.63 Billion ≈ $76.33 Million	-5.45%
2021-12-31	₩119.12 Billion ≈ $80.73 Million	+94.32%
2020-12-31	₩61.30 Billion ≈ $41.54 Million	+0.06%
2019-12-31	₩61.27 Billion ≈ $41.52 Million	+12.82%
2018-12-31	₩54.30 Billion ≈ $36.80 Million	+102.44%
2017-12-31	₩26.83 Billion ≈ $18.18 Million	-5.77%
2016-12-31	₩28.47 Billion ≈ $19.29 Million	+74.28%
2015-12-31	₩16.33 Billion ≈ $11.07 Million	-6.94%
2012-12-31	₩17.55 Billion ≈ $11.89 Million	+15.89%
2011-12-31	₩15.14 Billion ≈ $10.26 Million	+34.71%
2010-12-31	₩11.24 Billion ≈ $7.62 Million	+162.52%
2009-12-31	₩4.28 Billion ≈ $2.90 Million	--

About Genexine Inc

KQ:095700 Korea Biotechnology

Market Cap

$88.92 Million

₩131.21 Billion KRW

Market Cap Rank

#19741 Global

#1016 in Korea

Share Price

₩2885.00

Change (1 day)

-9.70%

52-Week Range

₩2840.00 - ₩7100.00

All Time High

₩131402.78